ENSG00000171456 |
|
myelodysplastic syndrome |
missense_variant |
14.62% (331/2264) |
10 entries |
ENSG00000171456 |
|
Chronic Neutrophilic Leukemia |
stop_gained |
57.69% (15/26) |
2 entries |
ENSG00000171456 |
|
Myelodysplastic/Myeloproliferative Neoplasm |
stop_gained |
24.56% (14/57) |
3 entries |
ENSG00000171456 |
|
acute myeloid leukemia |
missense_variant |
6.988% (604/8644) |
15 entries |
ENSG00000171456 |
|
acute myeloid leukemia |
sequence_alteration |
6.988% (604/8644) |
8 entries |
ENSG00000171456 |
|
Chronic Neutrophilic Leukemia |
frameshift_variant |
57.69% (15/26) |
3 entries |
ENSG00000171456 |
|
myelodysplastic syndrome |
stop_gained |
14.62% (331/2264) |
15 entries |
ENSG00000171456 |
|
myelodysplastic syndrome |
frameshift_variant |
14.62% (331/2264) |
23 entries |
ENSG00000171456 |
|
chronic myelomonocytic leukemia |
stop_gained |
38.74% (516/1332) |
19 entries |
ENSG00000171456 |
|
Myelodysplastic/Myeloproliferative Neoplasm |
sequence_alteration |
24.56% (14/57) |
1 entry |
ENSG00000171456 |
|
acute myeloid leukemia |
stop_gained |
6.988% (604/8644) |
25 entries |
ENSG00000171456 |
|
chronic myelomonocytic leukemia |
missense_variant |
38.74% (516/1332) |
7 entries |
ENSG00000171456 |
|
myelodysplastic syndrome |
conservative_inframe_deletion |
14.62% (331/2264) |
2 entries |
ENSG00000171456 |
|
myelodysplastic syndrome |
sequence_alteration |
14.62% (331/2264) |
7 entries |
ENSG00000171456 |
|
acute myeloid leukemia |
conservative_inframe_deletion |
6.988% (604/8644) |
2 entries |
ENSG00000171456 |
|
Myelodysplastic/Myeloproliferative Neoplasm |
frameshift_variant |
24.56% (14/57) |
5 entries |
ENSG00000171456 |
|
chronic myelomonocytic leukemia |
frameshift_variant |
38.74% (516/1332) |
17 entries |
ENSG00000171456 |
|
chronic myelomonocytic leukemia |
sequence_alteration |
38.74% (516/1332) |
7 entries |
ENSG00000171456 |
|
acute myeloid leukemia |
frameshift_variant |
6.988% (604/8644) |
25 entries |
ENSG00000171456 |
|
Ampulla of Vater Carcinoma |
stop_gained |
15.74% (31/197) |
1 entry |
ENSG00000171456 |
|
cecum adenocarcinoma |
missense_variant |
8.178% (22/269) |
3 entries |
ENSG00000171456 |
|
kidney Wilms tumor |
stop_gained |
1.339% (13/971) |
1 entry |
ENSG00000171456 |
|
Mantle cell lymphoma |
sequence_alteration |
4.478% (3/67) |
1 entry |
ENSG00000171456 |
|
Gastrointestinal stromal tumor |
missense_variant |
1.351% (2/148) |
1 entry |
ENSG00000171456 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
3.246% (21/647) |
1 entry |
ENSG00000171456 |
|
colorectal adenocarcinoma |
missense_variant |
5.892% (71/1205) |
3 entries |
ENSG00000171456 |
|
chronic lymphocytic leukemia |
frameshift_variant |
1.564% (14/895) |
1 entry |
ENSG00000171456 |
|
kidney Wilms tumor |
missense_variant |
1.339% (13/971) |
1 entry |
ENSG00000171456 |
|
polycythemia vera |
stop_gained |
2.387% (9/377) |
2 entries |
ENSG00000171456 |
|
essential thrombocythemia |
frameshift_variant |
4.668% (33/707) |
7 entries |
ENSG00000171456 |
|
bile duct adenocarcinoma |
missense_variant |
2.057% (8/389) |
2 entries |
ENSG00000171456 |
|
lung adenocarcinoma |
missense_variant |
1.732% (44/2540) |
7 entries |
ENSG00000171456 |
|
diffuse large B-cell lymphoma |
stop_gained |
1.905% (8/420) |
3 entries |
ENSG00000171456 |
|
breast carcinoma |
frameshift_variant |
1.248% (20/1602) |
2 entries |
ENSG00000171456 |
|
Merkel cell skin cancer |
stop_gained |
4.301% (4/93) |
2 entries |
ENSG00000171456 |
|
prostate carcinoma |
missense_variant |
2.727% (12/440) |
2 entries |
ENSG00000171456 |
|
brain glioblastoma |
frameshift_variant |
0.8244% (10/1213) |
1 entry |
ENSG00000171456 |
|
clear cell renal carcinoma |
missense_variant |
0.7079% (11/1554) |
3 entries |
ENSG00000171456 |
|
breast ductal adenocarcinoma |
stop_gained |
2.986% (49/1641) |
1 entry |
ENSG00000171456 |
|
leiomyosarcoma |
missense_variant |
4.202% (5/119) |
2 entries |
ENSG00000171456 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.6676% (5/749) |
2 entries |
ENSG00000171456 |
|
prostate adenocarcinoma |
missense_variant |
2.457% (53/2157) |
2 entries |
ENSG00000171456 |
|
multiple myeloma |
stop_gained |
6.316% (6/95) |
1 entry |
ENSG00000171456 |
|
lobular breast carcinoma |
missense_variant |
1.544% (4/259) |
1 entry |
ENSG00000171456 |
|
oral squamous cell carcinoma |
missense_variant |
1.894% (5/264) |
3 entries |
ENSG00000171456 |
|
breast carcinoma |
missense_variant |
1.248% (20/1602) |
1 entry |
ENSG00000171456 |
|
colorectal adenocarcinoma |
frameshift_variant |
5.892% (71/1205) |
3 entries |
ENSG00000171456 |
|
urothelial carcinoma |
missense_variant |
4.651% (4/86) |
1 entry |
ENSG00000171456 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
1.895% (13/686) |
3 entries |
ENSG00000171456 |
|
Hodgkins lymphoma |
stop_gained |
3.704% (3/81) |
2 entries |
ENSG00000171456 |
|
colon adenocarcinoma |
missense_variant |
4.908% (64/1304) |
8 entries |
ENSG00000171456 |
|
squamous cell lung carcinoma |
missense_variant |
2.361% (22/932) |
3 entries |
ENSG00000171456 |
|
cecum adenocarcinoma |
frameshift_variant |
8.178% (22/269) |
1 entry |
ENSG00000171456 |
|
esophageal adenocarcinoma |
sequence_alteration |
5.119% (28/547) |
1 entry |
ENSG00000171456 |
|
colorectal adenocarcinoma |
stop_gained |
5.892% (71/1205) |
2 entries |
ENSG00000171456 |
|
rectal adenocarcinoma |
stop_gained |
2.747% (15/546) |
1 entry |
ENSG00000171456 |
|
prostate adenocarcinoma |
frameshift_variant |
2.457% (53/2157) |
2 entries |
ENSG00000171456 |
|
skin melanoma |
missense_variant |
2.754% (32/1162) |
3 entries |
ENSG00000171456 |
|
essential thrombocythemia |
missense_variant |
4.668% (33/707) |
2 entries |
ENSG00000171456 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
3.246% (21/647) |
1 entry |
ENSG00000171456 |
|
large cell lung carcinoma |
missense_variant |
10.53% (2/19) |
2 entries |
ENSG00000171456 |
|
Myelodysplastic/Myeloproliferative Neoplasm |
missense_variant |
24.56% (14/57) |
1 entry |
ENSG00000171456 |
|
colorectal adenocarcinoma |
sequence_alteration |
5.892% (71/1205) |
3 entries |
ENSG00000171456 |
|
colon adenocarcinoma |
frameshift_variant |
4.908% (64/1304) |
7 entries |
ENSG00000171456 |
|
prostate adenocarcinoma |
stop_gained |
2.457% (53/2157) |
1 entry |
ENSG00000171456 |
|
rectal adenocarcinoma |
frameshift_variant |
2.747% (15/546) |
2 entries |
ENSG00000171456 |
|
clear cell renal carcinoma |
stop_gained |
0.7079% (11/1554) |
1 entry |
ENSG00000171456 |
|
polycythemia vera |
frameshift_variant |
2.387% (9/377) |
5 entries |
ENSG00000171456 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
2.128% (2/94) |
2 entries |
ENSG00000171456 |
|
rectal adenocarcinoma |
missense_variant |
2.747% (15/546) |
4 entries |
ENSG00000171456 |
|
anaplastic oligodendroglioma |
frameshift_variant |
3.333% (3/90) |
1 entry |
ENSG00000171456 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
2.273% (6/264) |
1 entry |
ENSG00000171456 |
|
endometrial stromal sarcoma |
missense_variant |
15.0% (3/20) |
1 entry |
ENSG00000171456 |
|
kidney Wilms tumor |
frameshift_variant |
1.339% (13/971) |
2 entries |
ENSG00000171456 |
|
brain glioblastoma |
missense_variant |
0.8244% (10/1213) |
2 entries |
ENSG00000171456 |
|
gastric adenocarcinoma |
frameshift_variant |
2.132% (20/938) |
1 entry |
ENSG00000171456 |
|
cecum adenocarcinoma |
stop_gained |
8.178% (22/269) |
2 entries |
ENSG00000171456 |
|
Chronic Eosinophilic Leukemia, Not Otherwise Specified |
frameshift_variant |
11.86% (7/59) |
1 entry |
ENSG00000171456 |
|
non-small cell lung carcinoma |
stop_gained |
2.646% (5/189) |
1 entry |
ENSG00000171456 |
|
essential thrombocythemia |
stop_gained |
4.668% (33/707) |
4 entries |
ENSG00000171456 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
3.246% (21/647) |
1 entry |
ENSG00000171456 |
|
Chronic Eosinophilic Leukemia, Not Otherwise Specified |
stop_gained |
11.86% (7/59) |
1 entry |
ENSG00000171456 |
|
Sinonasal Undifferentiated Carcinoma |
frameshift_variant |
16.67% (2/12) |
2 entries |
ENSG00000171456 |
|
esophageal squamous cell carcinoma |
missense_variant |
1.895% (13/686) |
3 entries |
ENSG00000171456 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
4.082% (4/98) |
2 entries |
ENSG00000171456 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.564% (14/895) |
1 entry |
ENSG00000171456 |
|
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
frameshift_variant |
11.32% (6/53) |
1 entry |
ENSG00000171456 |
|
melanoma |
missense_variant |
10.34% (15/145) |
3 entries |
ENSG00000171456 |
|
Dysplasia in Ulcerative Colitis |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000171456 |
|
oral squamous cell carcinoma |
stop_gained |
1.894% (5/264) |
2 entries |
ENSG00000171456 |
|
breast ductal adenocarcinoma |
missense_variant |
2.986% (49/1641) |
2 entries |
ENSG00000171456 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
1.581% (27/1708) |
1 entry |
ENSG00000171456 |
|
chronic myelogenous leukemia |
frameshift_variant |
10.04% (26/259) |
5 entries |
ENSG00000171456 |
|
squamous cell lung carcinoma |
stop_gained |
2.361% (22/932) |
1 entry |
ENSG00000171456 |
|
Brain Stem Glioblastoma |
stop_gained |
3.571% (2/56) |
1 entry |
ENSG00000171456 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.716% (6/838) |
2 entries |
ENSG00000171456 |
|
female breast carcinoma |
missense_variant |
1.404% (4/285) |
1 entry |
ENSG00000171456 |
|
salivary gland squamous cell carcinoma |
stop_gained |
100.0% (2/2) |
1 entry |
ENSG00000171456 |
|
papillary renal cell carcinoma |
missense_variant |
0.5195% (2/385) |
1 entry |
ENSG00000171456 |
|
chronic myelogenous leukemia |
stop_gained |
10.04% (26/259) |
5 entries |
ENSG00000171456 |
|
Chronic Neutrophilic Leukemia |
sequence_alteration |
57.69% (15/26) |
1 entry |
ENSG00000171456 |
|
gastric adenocarcinoma |
missense_variant |
2.132% (20/938) |
2 entries |
ENSG00000171456 |
|
Merkel cell skin cancer |
missense_variant |
4.301% (4/93) |
1 entry |
ENSG00000171456 |
|
Thyroid Gland Mucosa-Associated Lymphoid Tissue Lymphoma |
frameshift_variant |
40.0% (2/5) |
1 entry |
ENSG00000171456 |
|
multiple myeloma |
frameshift_variant |
6.316% (6/95) |
1 entry |
ENSG00000171456 |
|
chronic lymphocytic leukemia |
stop_gained |
1.564% (14/895) |
2 entries |
ENSG00000171456 |
|
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
stop_gained |
11.32% (6/53) |
3 entries |
ENSG00000171456 |
|
bladder transitional cell carcinoma |
missense_variant |
1.307% (6/459) |
1 entry |
ENSG00000171456 |
|
Ampulla of Vater Carcinoma |
frameshift_variant |
15.74% (31/197) |
1 entry |
ENSG00000171456 |
|
chronic myelogenous leukemia |
conservative_inframe_deletion |
10.04% (26/259) |
1 entry |
ENSG00000171456 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
2.273% (6/264) |
1 entry |
ENSG00000171456 |
|
Mast Cell Neoplasm |
frameshift_variant |
12.0% (9/75) |
2 entries |
ENSG00000171456 |
|
breast carcinoma |
stop_gained |
1.248% (20/1602) |
3 entries |
ENSG00000171456 |
|
esophageal adenocarcinoma |
missense_variant |
5.119% (28/547) |
2 entries |
ENSG00000171456 |
|
hemangioblastoma |
missense_variant |
5.714% (2/35) |
1 entry |
ENSG00000171456 |
|
breast tumor luminal |
missense_variant |
4.762% (2/42) |
1 entry |
ENSG00000171456 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
0.974% (3/308) |
2 entries |
ENSG00000171456 |
|
essential thrombocythemia |
conservative_inframe_deletion |
4.668% (33/707) |
2 entries |
ENSG00000171456 |
|
myeloproliferative disorder |
sequence_alteration |
6.024% (5/83) |
1 entry |
ENSG00000171456 |
|
prostate carcinoma |
sequence_alteration |
2.727% (12/440) |
1 entry |
ENSG00000171456 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
0.8639% (4/463) |
2 entries |
ENSG00000171456 |
|
colon adenocarcinoma |
stop_gained |
4.908% (64/1304) |
3 entries |
ENSG00000171456 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
0.8639% (4/463) |
2 entries |
ENSG00000171456 |
|
hepatocellular carcinoma |
missense_variant |
1.927% (19/986) |
2 entries |
ENSG00000171456 |
|
acute leukemia of ambiguous lineage |
stop_gained |
7.018% (8/114) |
1 entry |
ENSG00000171456 |
|
myeloproliferative disorder |
missense_variant |
6.024% (5/83) |
1 entry |
ENSG00000171456 |
|
metaplastic breast carcinoma |
missense_variant |
5.0% (3/60) |
2 entries |
ENSG00000171456 |
|
rectal adenocarcinoma |
sequence_alteration |
2.747% (15/546) |
1 entry |
ENSG00000171456 |
|
Juvenile Myelomonocytic Leukemia |
stop_gained |
2.804% (3/107) |
2 entries |
ENSG00000171456 |
|
basal cell carcinoma |
missense_variant |
4.412% (3/68) |
2 entries |
ENSG00000171456 |
|
small cell lung carcinoma |
missense_variant |
1.136% (5/440) |
2 entries |
ENSG00000171456 |
|
HER2 Positive Breast Carcinoma |
sequence_alteration |
4.93% (7/142) |
1 entry |
ENSG00000171456 |
|
non-small cell lung carcinoma |
missense_variant |
2.646% (5/189) |
2 entries |
ENSG00000171456 |
|
lung adenocarcinoma |
stop_gained |
1.732% (44/2540) |
1 entry |
ENSG00000171456 |
|
anaplastic oligodendroglioma |
missense_variant |
3.333% (3/90) |
1 entry |
ENSG00000171456 |
|
ulcerative colitis |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000171456 |
|
neoplasm |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000171456 |
|
ependymoma |
stop_gained |
1.852% (1/54) |
1 entry |
ENSG00000171456 |
|
angiosarcoma |
stop_gained |
3.509% (2/57) |
1 entry |
ENSG00000171456 |
|
breast ductal adenocarcinoma |
frameshift_variant |
2.986% (49/1641) |
1 entry |
ENSG00000171456 |
|
diffuse gastric adenocarcinoma |
stop_gained |
1.22% (1/82) |
1 entry |
ENSG00000171456 |
|
urothelial carcinoma |
frameshift_variant |
4.651% (4/86) |
1 entry |
ENSG00000171456 |
|
Mast Cell Neoplasm |
sequence_alteration |
12.0% (9/75) |
1 entry |
ENSG00000171456 |
|
leiomyoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000171456 |
|
papillary thyroid carcinoma |
stop_gained |
0.5917% (3/507) |
1 entry |
ENSG00000171456 |
|
laryngeal squamous cell carcinoma |
missense_variant |
4.878% (2/41) |
1 entry |
ENSG00000171456 |
|
chromophobe renal cell carcinoma |
frameshift_variant |
0.6803% (1/147) |
1 entry |
ENSG00000171456 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000171456 |
|
papillary thyroid carcinoma |
missense_variant |
0.5917% (3/507) |
1 entry |
ENSG00000171456 |
|
Granulocytic Sarcoma |
frameshift_variant |
2.778% (1/36) |
1 entry |
ENSG00000171456 |
|
gastric tubular adenocarcinoma |
sequence_alteration |
50.0% (1/2) |
1 entry |
ENSG00000171456 |
|
Uterine Carcinosarcoma |
frameshift_variant |
6.757% (10/148) |
1 entry |
ENSG00000171456 |
|
Vulvar Squamous Cell Carcinoma |
missense_variant |
10.53% (2/19) |
1 entry |
ENSG00000171456 |
|
medulloblastoma |
sequence_alteration |
4.167% (1/24) |
1 entry |
ENSG00000171456 |
|
Duodenal Adenocarcinoma |
missense_variant |
11.76% (2/17) |
1 entry |
ENSG00000171456 |
|
Borderline Ovarian Mucinous Tumor |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000171456 |
|
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
missense_variant |
11.32% (6/53) |
1 entry |
ENSG00000171456 |
|
Mantle cell lymphoma |
missense_variant |
4.478% (3/67) |
1 entry |
ENSG00000171456 |
|
acute lymphoblastic leukemia |
stop_gained |
0.3049% (1/328) |
1 entry |
ENSG00000171456 |
|
melanoma |
stop_gained |
10.34% (15/145) |
1 entry |
ENSG00000171456 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
5.882% (2/34) |
1 entry |
ENSG00000171456 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
2.273% (6/264) |
1 entry |
ENSG00000171456 |
|
lung adenocarcinoma |
frameshift_variant |
1.732% (44/2540) |
1 entry |
ENSG00000171456 |
|
marginal zone B-cell lymphoma |
stop_gained |
3.125% (1/32) |
1 entry |
ENSG00000171456 |
|
Mast Cell Neoplasm |
missense_variant |
12.0% (9/75) |
1 entry |
ENSG00000171456 |
|
salivary gland carcinoma |
stop_gained |
3.03% (1/33) |
1 entry |
ENSG00000171456 |
|
gastric tubular adenocarcinoma |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000171456 |
|
malignant epithelioid mesothelioma |
sequence_alteration |
25.0% (1/4) |
1 entry |
ENSG00000171456 |
|
Pleural Epithelioid Mesothelioma |
frameshift_variant |
0.9804% (2/204) |
1 entry |
ENSG00000171456 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
1.895% (13/686) |
1 entry |
ENSG00000171456 |
|
female breast carcinoma |
stop_gained |
1.404% (4/285) |
1 entry |
ENSG00000171456 |
|
urothelial carcinoma |
sequence_alteration |
4.651% (4/86) |
1 entry |
ENSG00000171456 |
|
breast phyllodes tumor |
frameshift_variant |
0.885% (1/113) |
1 entry |
ENSG00000171456 |
|
renal cell carcinoma |
missense_variant |
1.493% (1/67) |
1 entry |
ENSG00000171456 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
0.9804% (2/204) |
1 entry |
ENSG00000171456 |
|
Duodenal Adenocarcinoma |
frameshift_variant |
11.76% (2/17) |
1 entry |
ENSG00000171456 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
2.457% (53/2157) |
1 entry |
ENSG00000171456 |
|
colonic neoplasm |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000171456 |
|
Uterine Carcinosarcoma |
stop_gained |
6.757% (10/148) |
1 entry |
ENSG00000171456 |
|
small cell lung carcinoma |
stop_gained |
1.136% (5/440) |
1 entry |
ENSG00000171456 |
|
adenosquamous lung carcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000171456 |
|
Vulvar Squamous Cell Carcinoma |
sequence_alteration |
10.53% (2/19) |
1 entry |
ENSG00000171456 |
|
leiomyosarcoma |
frameshift_variant |
4.202% (5/119) |
1 entry |
ENSG00000171456 |
|
Tracheal Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000171456 |
|
bladder transitional cell carcinoma |
frameshift_variant |
1.307% (6/459) |
1 entry |
ENSG00000171456 |
|
Juvenile Myelomonocytic Leukemia |
frameshift_variant |
2.804% (3/107) |
1 entry |
ENSG00000171456 |
|
Borderline Ovarian Mucinous Tumor |
sequence_alteration |
12.5% (1/8) |
1 entry |
ENSG00000171456 |
|
clear cell renal carcinoma |
sequence_alteration |
0.7079% (11/1554) |
1 entry |
ENSG00000171456 |
|
Vulvar Squamous Cell Carcinoma |
frameshift_variant |
10.53% (2/19) |
1 entry |
ENSG00000171456 |
|
Gallbladder Adenocarcinoma |
missense_variant |
0.6098% (1/164) |
1 entry |
ENSG00000171456 |
|
Pancreatic Acinar Cell Carcinoma |
frameshift_variant |
5.882% (2/34) |
1 entry |
ENSG00000171456 |
|
Uterine Carcinosarcoma |
missense_variant |
6.757% (10/148) |
1 entry |
ENSG00000171456 |
|
small cell lung carcinoma |
sequence_alteration |
1.136% (5/440) |
1 entry |
ENSG00000171456 |
|
diffuse large B-cell lymphoma |
frameshift_variant |
1.905% (8/420) |
1 entry |
ENSG00000171456 |
|
Fibroadenoma |
missense_variant |
1.19% (1/84) |
1 entry |
ENSG00000171456 |
|
oligoastrocytoma |
frameshift_variant |
5.263% (1/19) |
1 entry |
ENSG00000171456 |
|
Parathyroid Gland Carcinoma |
stop_gained |
2.857% (1/35) |
1 entry |
ENSG00000171456 |
|
angiosarcoma |
frameshift_variant |
3.509% (2/57) |
1 entry |
ENSG00000171456 |
|
pancreatic neuroendocrine tumor |
missense_variant |
3.39% (8/236) |
1 entry |
ENSG00000171456 |
|
brain glioblastoma |
stop_gained |
0.8244% (10/1213) |
1 entry |
ENSG00000171456 |
|
laryngeal squamous cell carcinoma |
sequence_alteration |
4.878% (2/41) |
1 entry |
ENSG00000171456 |
|
small intestinal adenocarcinoma |
frameshift_variant |
9.524% (2/21) |
1 entry |
ENSG00000171456 |
|
polycythemia vera |
missense_variant |
2.387% (9/377) |
1 entry |
ENSG00000171456 |
|
small intestinal adenocarcinoma |
missense_variant |
9.524% (2/21) |
1 entry |
ENSG00000171456 |
|
unspecified peripheral T-cell lymphoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000171456 |
|
diffuse large B-cell lymphoma |
missense_variant |
1.905% (8/420) |
1 entry |
ENSG00000171456 |
|
astrocytoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000171456 |
|
embryonal rhabdomyosarcoma |
frameshift_variant |
1.163% (1/86) |
1 entry |
ENSG00000171456 |
|
ovarian teratoma |
missense_variant |
1.786% (1/56) |
1 entry |
ENSG00000171456 |
|
laryngeal squamous cell carcinoma |
frameshift_variant |
4.878% (2/41) |
1 entry |
ENSG00000171456 |
|
multiple myeloma |
missense_variant |
6.316% (6/95) |
1 entry |
ENSG00000171456 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000171456 |
|
melanoma |
frameshift_variant |
10.34% (15/145) |
1 entry |
ENSG00000171456 |
|
hepatocellular carcinoma |
frameshift_variant |
1.927% (19/986) |
1 entry |
ENSG00000171456 |
|
pharyngeal squamous cell carcinoma |
frameshift_variant |
0.6993% (1/143) |
1 entry |
ENSG00000171456 |
|
acute leukemia of ambiguous lineage |
missense_variant |
7.018% (8/114) |
1 entry |
ENSG00000171456 |
|
hepatocellular carcinoma |
stop_gained |
1.927% (19/986) |
1 entry |
ENSG00000171456 |
|
colon carcinoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000171456 |
|
lung adenocarcinoma |
sequence_alteration |
1.732% (44/2540) |
1 entry |
ENSG00000171456 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
4.93% (7/142) |
1 entry |
ENSG00000171456 |
|
osteosarcoma |
missense_variant |
0.6579% (1/152) |
1 entry |
ENSG00000171456 |
|
bladder transitional cell carcinoma |
stop_gained |
1.307% (6/459) |
1 entry |
ENSG00000171456 |
|
Therapy-Related Myeloid Neoplasm |
missense_variant |
2.632% (1/38) |
1 entry |
ENSG00000171456 |
|
clear cell renal carcinoma |
frameshift_variant |
0.7079% (11/1554) |
1 entry |
ENSG00000171456 |
|
Thymic Carcinoma |
sequence_alteration |
6.667% (1/15) |
1 entry |
ENSG00000171456 |
|
Duodenal Adenocarcinoma |
stop_gained |
11.76% (2/17) |
1 entry |
ENSG00000171456 |
|
Ovarian Small Cell Carcinoma |
frameshift_variant |
6.667% (1/15) |
1 entry |
ENSG00000171456 |
|
papillary thyroid carcinoma |
frameshift_variant |
0.5917% (3/507) |
1 entry |
ENSG00000171456 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
0.716% (6/838) |
1 entry |
ENSG00000171456 |
|
basal cell carcinoma |
sequence_alteration |
4.412% (3/68) |
1 entry |
ENSG00000171456 |
|
breast carcinoma |
conservative_inframe_deletion |
1.248% (20/1602) |
1 entry |
ENSG00000171456 |
|
angioimmunoblastic T-cell lymphoma |
frameshift_variant |
0.9091% (1/110) |
1 entry |